A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor

PHASE1RecruitingINTERVENTIONAL
Enrollment

111

Participants

Timeline

Start Date

August 12, 2024

Primary Completion Date

June 24, 2026

Study Completion Date

February 1, 2028

Conditions
Advanced Solid TumorsRefractory LymphomaRelapsed Hematologic Malignancy
Interventions
DRUG

HDM2005

HDM2005 will be administered via IV infusion.

Trial Locations (8)

Unknown

NOT_YET_RECRUITING

Henan Cancer Hospital, Zhengzhou

RECRUITING

The First Affiliated Hospital of Soochow University, Suzhou

RECRUITING

The Second Affiliated Hospital of Soochow University, Suzhou

RECRUITING

The Affiliated Hospital of Xuzhou Medical University, Xuzhou

NOT_YET_RECRUITING

The First Affiliated Hospital Of Nanchang University, Nanchang

NOT_YET_RECRUITING

Shandong Cancer Hospital, Jinan

NOT_YET_RECRUITING

The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou

RECRUITING

The Institute of Hematology and Blood Diseases Hospital at the Chinese Academy of Medical Sciences, Tianjing

All Listed Sponsors
lead

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

INDUSTRY